Icagen 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 12, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Icagen, Inc.
Entity Central Index Key	1,518,520
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,481,857

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current Assets
Cash	$ 925,668	$ 2,266,788
Accounts receivable, net	883,019	967,170
Prepaid expenses and other current assets	363,776	357,554
Investment in certificate of deposit	25,023	25,023
Assets held for resale	27,000	27,620
Total Current Assets	2,224,486	3,644,155
Non-Current Assets
Intangibles, net	7,611,382	7,723,873
Plant and equipment, net	1,887,333	1,561,582
Total Non-Current Assets	9,498,715	9,285,455
Total Assets	11,723,201	12,929,610
Current Liabilities
Accounts payable	923,638	934,710
Other payables and accrued expenses	443,371	518,608
Legal settlement accrual	698,500	1,164,750
Loans payable	546,859	164,381
Bridge notes	843,233
Deferred purchase consideration	250,000	125,000
Dividends payable	77	77
Total Current Liabilities	3,705,678	2,907,526
Non-Current Liabilities
Deferred purchase consideration, net	8,351,580	8,313,490
Total Non-Current Liabilities	8,351,580	8,313,490
Total Liabilities	12,057,258	11,221,016
Convertible Redeemable Preferred stock
Series A cumulative convertible redeemable Preferred stock, $0.001 par value, 400,000 shares designated, nil and 105,000 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively, liquidation preference $5.70 per share		133,350
Commitment and contingencies
Stockholders' (Deficit) Equity
Preferred stock, $0.001 par value, 10,000,000 authorized, 3,000,000shares designated as Series B Preferred stock, 6,600,000 undesignated and unissued
Common stock, $0.001 par value; 50,000,000 shares authorized, 6,808,857 shares issued and 6,481,857 outstanding as of June 30, 2016 and December 31, 2015.	6,482	6,482
Additional paid-in-capital	24,093,487	23,711,824
Treasury stock, at cost (327,000 shares of common stock at June 30, 2016 and December 31, 2015).	(237)	(237)
Accumulated deficit	(24,433,789)	(22,142,825)
Total stockholder's (Deficit) Equity	(334,057)	1,575,244
Total Liabilities and Stockholders' (Deficit) Equity	$ 11,723,201	$ 12,929,610

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Preferred stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	6,808,457	6,808,857
Common stock, shares outstanding	6,481,457	6,481,457
Treasury stock, shares	327,000	327,000
Series A Preferred Stock
Convertible redeemable preferred stock, par value	$ 0.001	$ 0.001
Convertible redeemable preferred stock, shares designated	400,000	400,000
Convertible redeemable preferred stock, shares issued		105,000
Convertible redeemable preferred stock, shares outstanding		105,000
Convertible redeemable preferred stock, liquidation preference per share	$ 5.70	$ 5.70
Series B Preferred Stock [Member]
Preferred stock designated shares	3,000,000	3,000,000
Preferred stock undesignated and unissued shares	6,600,000	6,600,000

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statements of Operations [Abstract]
Sales	$ 1,157,458	$ 95,158	$ 2,058,324	$ 125,811
Cost of sales	840,995	129,666	1,535,845	291,867
Gross profit (loss)	316,463	(34,508)	522,479	(166,056)
Operating expenses:
Selling, general and administrative expenses	1,178,467	1,239,031	2,190,238	2,490,105
Depreciation	112,304	32,823	213,881	65,049
Amortization	56,246	12,921	112,492	25,842
Total Operating expenses	1,347,017	1,284,775	2,516,611	2,580,996
Operating loss	(1,030,554)	(1,319,283)	(1,994,132)	(2,747,052)
Other (expense) income
Other (expense) income		(6,400)		(6,239)
Interest income	46	1,562	335	3,416
Interest expense	(150,928)	(2,042)	(297,166)	(4,206)
Total other expense	(150,882)	(6,880)	(296,831)	(7,029)
Net loss before income tax	(1,181,436)	(1,326,163)	(2,290,963)	(2,754,081)
Income tax
Net loss	(1,181,436)	(1,326,163)	(2,290,963)	(2,754,081)
Preferred stock dividends		(12,042)		(72,697)
Net loss applicable to common stock	$ (1,181,436)	$ (1,338,205)	$ (2,290,963)	$ (2,826,778)
Net Loss Per Share - Basic and Diluted	$ (0.18)	$ (0.21)	$ (0.35)	$ (0.47)
Weighted Average Number of Shares Outstanding -Basic and Diluted	6,481,857	6,464,614	6,481,857	6,061,120

Unaudited Condensed Consolidat5

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,290,963)	$ (2,754,081)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation expense	213,881	65,049
Amortization expense	112,492	25,842
Stock based compensation charge	228,849	293,425
Imputed interest charge	294,986
Movement in bad debts provision	(19,084)
Loss on disposal of plant and equipment		6,239
Increase in legal settlement accrual		85,000
Changes in operating assets and liabilities
Accounts receivable	103,235	21,541
Prepaid expenses and other current assets	(5,602)	(244,627)
Accounts payable	(11,072)	122,400
Other payables and accrued expenses	(723,983)	34,349
CASH USED IN OPERATING ACTIVITIES	(2,097,261)	(2,344,863)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment of deferred purchase consideration	(125,000)
Purchase of plant and equipment	(539,632)	(59,478)
Proceeds on sale of plant and equipment		934
Investment in deposits		(5)
NET CASH USED IN INVESTING ACTIVITIES	(664,632)	(58,549)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of Los Alamos County loan	(142,311)	(17,038)
Repayment of software loan	(15,206)
Proceeds from equipment loan	533,290
Proceeds from bridge notes	1,045,000
Proceeds from common stock units issued		3,836,133
Share issue expenses		(314,541)
Warrants exercised		400
Series A Preferred Stock dividend paid		(48,300)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	1,420,773	3,456,654
NET (DECREASE) INCREASE IN CASH	(1,341,120)	1,053,242
Cash at the beginning of the period	2,266,788	6,472,393
CAST AT END OF PERIOD	925,668	7,525,635
CASH PAID FOR INTEREST AND TAXES:
Cash paid for income taxes
Cash paid for interest	3,435	4,244
NON-CASH INVESTING AND FINANCING ACTIVITIES
Value of Series A stock redeemed offset against stockholders' equity	(50,400)
Value of warrants issued concurrent with bridge notes	203,214
Common stock issued in exchange for Series B Preferred stock		2,134
Common stock issued in lieu of Series B Preferred stock dividend		978,417
Common shares issued to partially settle liability		310,625
Accrued Series A Preferred Stock dividends		23,952
Accrued Series B Preferred Stock dividends		$ 48,745

General Information

General Information	6 Months Ended
	Jun. 30, 2016
General Information [Abstract]
GENERAL INFORMATION	1. GENERAL INFORMATION Icagen, Inc. (“the Company”, “we”, “us”, “our”) is a Delaware corporation. The principal office is located in Research Triangle Park, Durham, North Carolina. The Company was incorporated in November 2003.

Accounting Policies and Estimat

Accounting Policies and Estimates	6 Months Ended
	Jun. 30, 2016
Accounting Policies and Estimates [Abstract]
ACCOUNTING POLICIES AND ESTIMATES	2. ACCOUNTING POLICIES AND ESTIMATES General The following (a) consolidated balance sheets as of June 30, 2016 which have been derived from the unaudited condensed consolidated financial statements and December 31, 2015, which have been derived from audited consolidated financial statements, and (b) the unaudited interim statements of operations and cash flows of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months and six months ended June 30, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2016. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission (“SEC”) on April 14, 2016. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments necessary to fairly present the results for the interim periods presented have been made. All adjustments made are of a normal and recurring nature and no non-recurring adjustments have been made in the presentation of these interim financial statements. All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise. Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has a majority voting interest. Investments in affiliates are accounted for under the cost method of accounting, where appropriate. All significant inter-company accounts and transactions have been eliminated in the condensed consolidated financial statements. The entities included in these condensed consolidated financial statements are as follows: Icagen, Inc. - Parent Company Icagen Corp (formerly known as XRpro Corp.) - Wholly owned subsidiary Icagen-T Inc. – Wholly owned subsidiary (formed on June 16, 2016) Caldera Discovery, Inc. - Wholly owned subsidiary (formed on March 27, 2015) XRpro Sciences, Inc. – Wholly owned subsidiary (formed on December 10, 2015) Estimates The preparation of these consolidated financial statements in accordance with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts and recovery of long-lived assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, the valuation of certain assets and intangibles acquired from Icagen, and assumptions used in assessing impairment of long-term assets and the assumptions used in determining percentage of completion on our long-term contracts. Concentrations of credit risk The Company maintains cash with major financial institutions. The Federal Deposit Insurance Corporation (“FDIC”) provides insurance coverage for deposits of corporations, the current limit of coverage is $250,000. As a result of this coverage the Company has cash balances of $555,190 that are not covered by the FDIC as of June 30, 2016. Concentration of major customers The Company derives its revenues from commercial pharmaceutical and biotechnology companies as well as from Government research contracts and Government grants. Total revenues by customer type are as follows: Three months ended June 30, 2016 Three months ended June 30, 2015 Six months ended June 30, 2016 Six months ended June 30, 2015 National Institutes of Health $ 151,403 $ 95,158 $ 266,269 $ 125,811 Commercial revenues 1,006,055 - 1,792,055 - $ 1,157,458 $ 95,158 $ 2,058,324 $ 125,811 Accounts receivable and other receivables We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. As a basis for accurately estimating the likelihood of collection of our accounts receivable, we consider a number of factors when determining reserves for uncollectable accounts. We believe that we use a reasonably reliable methodology to estimate the collectability of our accounts receivable. We review our allowances for doubtful accounts on a regular basis. We also consider whether the historical economic conditions are comparable to current economic conditions. If the financial condition of our customers or other parties that we have business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The balance of the receivables provision as at June 30, 2016 and December 31, 2015 was $Nil and $19,084, respectively. The amount charged to bad debt provision for the three months and six months ended June 30, 2016 was $19,084 and for the three months and six months ended June 30, 2015 was $0. Revenue recognition Revenue sources consist of commercial contracts, government grants and government contracts. We enter into fixed fee commercial development contracts that are not associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under such contracts is generally recognized upon delivery or as the development is performed. We account for our long-term Firm Fixed Price Government contracts and grants associated with the delivery of research on drug candidates and the development of drug candidates using the percentage-of-completion accounting method. Under this method, revenue is recognized based on the extent of progress towards completion of the long-term contract. We generally use the cost-to-cost measure of progress for all of our long-term contracts, unless we believe another measure will produce a more reliable result. We believe that the cost-to-cost measure is the best and most reliable performance indicator of progress on our long-term contracts as all our contract estimates are based on costs that we expect to incur in performing our long-term contracts and we have not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the long-term contract. Revenues, including estimated fees or profits are recorded as costs are incurred. When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined. Research and Development The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred. Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life. The amount expensed for unrecovered research costs, included in Selling, general and administrative expenses during the three months and six months ended June 30, 2016 was $Nil and for the three months and six months ended June 30, 2015 was $75,034 and $102,900, respectively. Related parties Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged. Property purchased from a related party is recorded at the cost to the related party and any payment to or on behalf of the related party in excess of the cost is reflected as a distribution to the related party. Recent accounting pronouncements In April 2016, the Financial Accounting Standards Board (FASB) issued an Accounting Standards Update (ASU) “ASU 2016 – 10 Revenue from Contract with Customers: identifying Performance Obligations and Licensing”. The amendments in this Update clarify the two following aspects (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments in this Update are intended to reduce the degree of judgement necessary to comply with Topic 606. This guidance has no effective date as yet. The Company is currently evaluating the impact of adopting this guidance. Any new accounting standards, not disclosed above, that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2016
Going Concern [Abstract]
GOING CONCERN	3. GOING CONCERN The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, the Company incurred a net loss of $(2,290,963) for the six months ended June 30, 2016 and $(8,676,037) for the year ended December 31, 2015. As of June 30, 2016 and December 31, 2015, the Company had accumulated deficits of $24,433,789 and $22,142,825, respectively. The Company’s working capital decreased from $736,629 at December 31, 2015 to a deficit of $1,481,192 as at June 30, 2016. The Company’s working capital is insufficient to meet its short-term cash requirements and fund any future operating losses. These operating losses create an uncertainty about the Company’s ability to continue as a going concern. The Company’s plan, through the acquisition of the assets of Icagen and the continued promotion of its services to existing and potential customers is to generate sufficient revenues to cover our anticipated expenses. The Company is currently exploring several options to meet its short-term cash requirements, including bridge note funding, an equity raise or loan funding from third parties. Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, the management of the Company believes that the revenue to be generated from operations together with potential bridge note funding, additional issuances of equity or other potential financing will provide the necessary funding for the Company to continue as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is economically dependent upon future capital contributions or financing to fund ongoing operations.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2016
Prepaid Expenses and Other Current Assets [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	4. PREPAID EXPENSES AND OTHER CURRENT ASSETS June 30, December 31, Prepaid insurance $ 46,445 $ 19,714 Prepaid rent 2,500 2,500 Prepaid equipment maintenance 2,160 15,123 Prepaid Subscriptions 1,881 5,106 Surety bond 310,000 310,000 Other 790 5,111 $ 363,776 $ 357,554 A surety bond of $310,000 was posted as security for the sanctions levied against the Company in the Litigation with the Estate of Sigmund Eisenschenk, the bond was necessary and the Company has appealed these sanctions (refer note 19 below).

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2016
Intangible Assets [Abstract]
INTANGIBLE ASSETS	5. INTANGIBLE ASSETS Intangible assets consist of the following: June 30, December 31, Cost Amortization and impairment Net book value Net book value Cell lines $ 5,000,500 $ - $ 5,000,500 $ 5,000,500 Biology platform 1,450,500 (145,050 ) 1,305,450 1,377,975 Trade name and trademarks 637,500 - 637,500 637,500 Assembled workforce 282,500 (28,250 ) 254,250 268,375 Patents 972,000 (558,318 ) 413,682 439,523 $ 8,343,000 $ (713,618 ) $ 7,611,382 $ 7,723,873 The aggregate amortization expense charged to operations was $56,246 and $12,921 for the three months ended June 30, 2016 and 2015, respectively, and $112,492 and $25,842 for the six months ended June 30, 2016 and 2015, respectively. Amortization expense for future periods is summarized as follows: Amount 2016 $ 112,492 2017 224,984 2018 224,984 2019 224,984 2020 224,984 2021 and thereafter 960,954 Total $ 1,973,382

Plant and Equipment

Plant and Equipment	6 Months Ended
	Jun. 30, 2016
Plant and Equipment [Abstract]
PLANT AND EQUIPMENT	6. PLANT AND EQUIPMENT Plant and equipment consists of the following: June 30, December 31, Cost Amortization and impairment Net book value Net book value Leasehold improvements $ 4,263 $ (964 ) $ 3,299 $ 3,960 Laboratory equipment 2,333,017 (588,497 ) 1,744,520 1,339,119 Computer Software 253,028 (133,180 ) 119,848 194,076 Computer equipment 28,572 (8,906 ) 19,666 24,427 $ 2,618,880 $ (731,547 ) $ 1,887,333 $ 1,561,582 The aggregate depreciation charge to operations was $112,304 and $ 32,823 for the three months ended June 30, 2016 and 2015, respectively, and $213,881 and $65,049 for the six months ended June 30, 2016 and 2015, respectively.

Other Payables and Accrued Expe

Other Payables and Accrued Expenses	6 Months Ended
	Jun. 30, 2016
Other Payables and Accrued Expenses [Abstract]
OTHER PAYABLES AND ACCRUED EXPENSES	7. OTHER PAYABLES AND ACCRUED EXPENSES June 30, December 31, Credit card liabilities $ 7,254 $ - Vacation and Sick Pay accrual 104,281 93,104 Payroll liabilities 271,062 174,399 Severance cost accrual - 67,315 Other 60,774 183,790 $ 443,371 $ 518,608

Legal Settlement Liabilities

Legal Settlement Liabilities	6 Months Ended
	Jun. 30, 2016
Legal Settlement Liabilities\Commitments and Contingencies [Abstract]
LEGAL SETTLEMENT LIABILITIES	8. LEGAL SETTLEMENT LIABILITIES The legal settlement liability is disclosed as follows: June 30, December 31, Legal Settlement accrual – Bellows matter $ - $ 466,250 Legal settlement accrual – Eisenschenk matter 516,250 516,250 Legal settlement – other 10,000 10,000 Judgement liability 172,250 172,250 $ 698,500 $ 1,164,750 Pursuant to the terms of a settlement agreement reached with Bellows on September 28, 2015, the Company agreed to settle all legal matters with Bellows for a cash settlement of $1,650,000, with Bellows surrendering into escrow the 105,000 Series A preferred shares currently held by him and relinquishing his rights to any further dividend payments on those shares. This amount has been repaid in full and the escrow Series A preferred shares were released to the Company. See note 12 below.

Loans Payable

Loans Payable	6 Months Ended
	Jun. 30, 2016
Loans Payable [Abstract]
LOANS PAYABLE	9. LOANS PAYABLE Loans payable consist of the following: June 30, December 31, Short term portion Los Alamos County project participation loan $ - $ 142,502 Asset leasing arrangement 540,186 - Asset funding agreement 6,673 21,879 Total $ 546,859 $ 164,381 The amortization of the principal outstanding on the loans payable is as follows: Amount Within 1 year $ 546,859 Los Alamos County project participation loan The Company owed $Nil and $142,502 as of June 30, 2016 and December 31, 2015, respectively. Due to the closure of the Los Alamos site, the loan was repaid on June 30, 2016. Asset leasing arrangement The Company acquired laboratory equipment from Nanion Technologies on April 21, 2016 in terms of a lease agreement. The lease consists of twelve equal monthly instalments of $28,751 each with a remaining balance due of $225,000 at the end of the twelve-month period. In terms of US GAAP, the total purchase consideration was discounted back to present value at the Company’s estimated weighted average cost of capital of 6.7%, resulting in an estimated present value of future payments of $533,290. The discount of $36,722 will be expensed as an additional interest expense over the estimated period in which the payments are expected to be made. The discount will be evaluated at each reporting period to determine if our assumptions are still valid. The Company owed $540,186 as of June 30, 2016, including imputed interest of $6,896. Asset funding arrangement The Company entered into a short term asset funding agreement for $26,062 to acquire certain software related to the Icagen acquisition. The term of the loan is for twelve months with 12 equal installments of $2,313. The interest rate on the loan is 11.8% per annum. The Company owed $6,673 and $26,062 as of June 30, 2016 and December 31, 2015, respectively.

Bridge Notes

Bridge Notes	6 Months Ended
	Jun. 30, 2016
Bridge Notes [Abstract]
BRIDGE NOTES	10. BRIDGE NOTES On June 30 2016, the Company sold in a private placement offering to 11 investors pursuant to a securities purchase agreement entered into with each investor, 104.5 units at a per unit price of $10,000, each unit (the “Units”) consisting of a note in the principal amount of $10,000 (the “Notes”) and a five-year warrant (the “Warrants”) to acquire 1,500 shares of the Company’s common stock, par value, $0.001 per share, at an exercise price of $3.50 per share for gross proceeds of $1,045,000. On July 7, 2016, the Company sold an additional 10 Units in the Offering to one investor for gross proceeds of $100,000. The aggregate cash proceeds to the Company from the sale of the 114.5 Units was $1,145,000. The Notes bear interest at a rate of 8% per annum and mature on June 30, 2017. Pursuant to a Security and Pledge Agreement the Notes are secured by a lien on all of the current assets of the Company (excluding the equity of and assets of the Company’s wholly owned subsidiary, Icagen-T, Inc.). Amounts overdue bear interest at a rate of 1% per month. The Warrants have an initial exercise price of $3.50 per share and are exercisable for a period of five years from the date of issuance. Each Warrant is exercisable for one share of Common Stock, which resulted in the issuance of Warrants exercisable to purchase an aggregate of 171,750 shares of Common Stock. The Warrants are subject to adjustment in the event of stock splits and other similar transactions. The warrants were valued using a Black-Scholes valuation model and the proceeds received were allocated based on the percentage of the warrants to the total value of the securities in this offering, resulting in a debt discount of $203,214 on the warrants issued prior to June 30, 2016. Subsequent to June 30, 2016, a further debt discount of $14,183 was recorded for Units issued on July 7, 2016. An additional $27,066 was allocated to the value of the placement agent warrants described below. The Company retained Taglich Brothers, Inc. as the exclusive placement agent for the Offering. In connection therewith, the Company agreed to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering ($1,145,000) and agreed to reimburse approximately $15,000 in respect of out of pocket expenses incurred by the placement agent in connection with the Offering. The Company also issued the placement agent the same warrant that the investors received exercisable for an aggregate amount of 28,625 shares of Common Stock at an exercise price of $3.50 per share (2,500 shares of Common Stock for each $100,000 in principal amount of Notes sold) (the “Placement Agent Warrants”). June 30, December 31, Short term portion Bridge notes $ 1,045,000 $ - Accrued interest 1,447 - Unamortized debt discount (203,214 ) - Total $ 843,233 $ - Subsequent to June 30, 2016, on August 8, 2016, these Bridge notes, together with interest thereon were repaid in full.

Deferred Purchase Consideration

Deferred Purchase Consideration	6 Months Ended
	Jun. 30, 2016
Deferred Purchase Consideration [Abstract]
DEFERRED PURCHASE CONSIDERATION	11. DEFERRED PURCHASE CONSIDERATION In terms of the Icagen asset purchase agreement entered into on July 1, 2015, the Company has the following deferred purchase price obligations: ● $500,000 is due on July 1, 2017, provided that Pfizer has generated at least $4,000,000 in revenue, there are no indications that the targets will not be met; ● commencing January 1, 2017, the Company is obligated to pay additional purchase price consideration calculated as 10% (ten percent) of gross revenues to Pfizer, Inc. This obligation is capped at a maximum of $10,000,000. These earn out payments are payable quarterly, 60 days after the completion of each calendar quarter, with a minimum payment of $250,000 per quarter. There are no indications that the Company will not meet the maximum earn out payment. Deferred purchase consideration is disclosed as follows: June 30, December 31, Short term portion Deferred purchase consideration $ 250,000 $ 125,000 Long term portion Deferred purchase consideration 10,250,000 10,500,000 10,500,000 10,625,000 Present value discount on future payments (2,468,700 ) (2,468,700 ) Imputed interest expense 570,280 282,190 Total $ 8,601,580 $ 8,438,490

Preferred Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2016
Common Stock and Preferred Stock [Abstract]
PREFERRED STOCK	12. PREFERRED STOCK Series A 8% Convertible, Redeemable Preferred Stock (“Series A Stock”) On September 28, 2015, the Company entered into a settlement agreement whereby Bellows surrendered into escrow his Series A shares to the Company. These shares were held in trust with the Company’s legal counsel until such time as the final installment had been paid. The company fulfilled all of its obligations under the settlement and the Series A shares were released from Escrow and subsequently cancelled. As of June 30, 2016 and December 31, 2015, there were Nil and 105,000 Series A Stock issued and outstanding, respectively.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2016
Common Stock and Preferred Stock [Abstract]
COMMON STOCK	13. COMMON STOCK On June 16, 2015, in terms of a restricted stock award, 19,000 restricted shares were issued to the Chairman of our audit committee who is also a board director, as a once off compensation expense for his services as chairman of the audit committee. As of June 30, 2016, all of these shares are vested. The restricted stock outstanding and exercisable at June 30, 2016 is as follows: Restricted Stock Outstanding Restricted Stock Exercisable Grant date Price Number Outstanding Weighted Average Number Vested Weighted Average $ 3.50 19,000 $ 3.50 19,000 $ 3.50 The Company has recorded an expense of $19,950 and $0 for the six months ended June 30, 2016 and 2015, respectively.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2016
Warrants [Abstract]
WARRANTS	14. WARRANTS Warrants exercisable for 131,374 shares of common stock at an exercise price of $11.40, expired during the six months ended June 30, 2016. In terms of the bridge note funding described in note 10 above, the Company sold in a private placement offering to 11 investors pursuant to a securities purchase agreement entered into with each investor, 104.5 units at a per unit price of $10,000, each unit (the “Units”) consisting of a note in the principal amount of $10,000 (the “Notes”) and a five-year warrant (the “Warrants”) to acquire 1,500 shares of the Company’s common stock, par value, $0.001 per share, at an exercise price of $3.50 per share for gross proceeds of $1,045,000. On July 7, 2016, the Company sold an additional 10 Units in the Offering to one investor for gross proceeds of $100,000. The aggregate cash proceeds to the Company from the sale of the 114.5 Units was $1,145,000. The Warrants have an initial exercise price of $3.50 per share and are exercisable for a period of five years from the date of issuance. Each Warrant is exercisable for one share of Common Stock, which resulted in the issuance of Warrants exercisable to purchase an aggregate of 171,750 shares of Common Stock. The Warrants are subject to adjustment in the event of stock splits and other similar transactions. The warrants were valued using a Black-Scholes valuation model and the proceeds received were allocated based on the percentage of the warrants to the total value of the securities in this offering, resulting in a debt discount of $203,214 on the warrants issued prior to June 30, 2016. Subsequent to June 30, 2016, a further debt discount of $14,183 was recorded for Units issued on July 7, 2106. An additional $27,066 was allocated to the value of the placement agent warrants described below. The fair value of warrants issued were valued using the Black-Scholes pricing model and the following weighted average assumptions were used: Six months ended Calculated stock price $ 3.50 Risk-free interest rate 1.01 % Expected life of warrants (in years) 5 Expected volatility of the underlying stock 53 % Expected dividend rate 0 % The volatility of the common stock is estimated using historical data of companies similar in size and in the same industry as the Company. The risk-free interest rate used in the Black-Scholes pricing model is determined by reference to historical U.S. Treasury constant maturity rates with maturities approximate to the life of the warrants granted. An expected dividend yield of zero is used in the valuation model, because the Company does not expect to pay any cash dividends in the foreseeable future. As of June 30, 2016, the Company does not anticipate any awards will be forfeited in the valuation of the warrants. A summary of all of our warrant activity during the period January 1, 2016 to June 30, 2016 is as follows: Shares Exercise price per share Weighted average exercise price Outstanding January 1, 2016 2,146,970 $ 3.50 -11.40 $ 4.28 Granted 156,750 3.50 3.50 Forfeited/Cancelled (131,374 ) 11.40 11.40 Exercised - - - Outstanding June 30, 2016 2,172,346 $ 3.50-11.40 $ 3.79 The following table summarizes warrants outstanding and exercisable as of June 30, 2016: Warrants Outstanding Warrants Exercisable Exercise Price Number of Weighted Weighted Number of Weighted $ 3.50 1,810,615 3.66 1,810,615 $ 3.85 143,401 4.00 143,401 $ 4.00 7,500 0.34 7,500 $ 4.20 150,000 1.66 150,000 $ 11.40 60,830 0.22 60,830 2,172,346 3.51 $ 3.79 2,172,346 $ 3.79

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2016
Stock Based Compensation [Abstract]
STOCK BASED COMPENSATION	15. STOCK BASED COMPENSATION Options exercisable for 110,000 and 72,282 shares of common stock for the six months ended June 30, 2016 and the year ended December 31, 2015, respectively that were held by employees and consultants under the 2005 Stock option plan were not exercised in terms of the option agreements entered into and have expired. The shares underlying such options were returned to and are no longer available for re-issuance under the 2005 Plan. On May 19, 2016, the Company issued ten-year options exercisable for 240,000 shares of common stock at $3.50 per common share to certain employees as incentive stock options, 220,000 of the options issued vest over a period of 48 months whilst 20,000 options are performance related, linked to certain revenue targets. On May 19, 2016, the Company issued ten-year options exercisable for 62,500 shares of common stock at $3.50 per common shares to certain of our directors as compensation for services rendered. These options vest equally over a period of 36 months. The fair value of options issued were valued using the Black-Scholes pricing model and the following weighted average assumptions were used: Six months ended Calculated stock price $ 3.50 Risk-free interest rate 1.81 % Expected life of options (in years) 10 Expected volatility of the underlying stock 61 % Expected dividend rate 0 % The volatility of the common stock is estimated using historical data of companies similar in size and in the same industry as the Company. The risk-free interest rate used in the Black-Scholes pricing model is determined by reference to historical U.S. Treasury constant maturity rates with maturities approximate to the life of the options granted. An expected dividend yield of zero is used in the valuation model, because the Company does not expect to pay any cash dividends in the foreseeable future. As of June 30, 2016, the Company does not anticipate any awards will be forfeited in the valuation of the options. A summary of all of our option activity during the period January 1, 2016 to June 30, 2016 is as follows: Shares Exercise price per share Weighted average exercise price Outstanding January 1, 2016 908,270 $ 0.40 -11.42 $ 3.60 Granted 302,500 3.50 3.50 Forfeited/Cancelled (110,000 ) 2.20 2.20 Exercised - - - Outstanding June 30, 2016 1,100,770 $ 0.40-11.42 $ 3.71 The following tables summarize information about stock options outstanding as of June 30, 2016: Options Outstanding Options Exercisable Exercise Price Number of Weighted Weighted Number of Weighted $ 0.40 15,000 5.84 15,000 $ 3.00 312,500 6.71 312,500 $ 3.50 552,500 9.27 110,925 $ 4.00 56,770 0.84 56,770 $ 5.00 128,500 4.49 120,167 $ 11.42 35,500 2.43 35,500 1,100,770 7.28 $ 3.77 650,862 $ 3.94 The weighted-average grant-date fair values of options granted during the six months ended June 30, 2016 was $736,066 ($2.43 per option) and for the year ended December 31, 2015 was $844,577 ($3.31 per option). As of June 30, 2016 there were unvested options to purchase 449,908 shares of common stock. Total expected unrecognized compensation cost related to such unvested options is $1,193,044, which is expected to be recognized over a period of 47 months. Stock option based compensation expense totaled $133,549 and $76,913 for the three months ended June 30, 2016 and $228,849 and $293,425 for the six months ended June 30, 2016 and 2015, respectively. Stock options outstanding as of June 30, 2016 as disclosed in the above table, have an intrinsic value of $202,750.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2016
Net Loss Per Common Share [Abstract]
NET LOSS PER COMMON SHARE	16. NET LOSS PER COMMON SHARE For the three months and six months ended June 30, 2016 and 2015, respectively, the following options, warrants and convertible preferred stock were excluded from the computation of diluted net loss per shares as the result of the computation was anti-dilutive: Three and Six months ended Three and Six months ended Options to purchase shares of common stock 1,100,770 932,228 Warrants 2,172,346 2,146,970 Series A convertible, redeemable preferred stock - 52,500 3,273,116 3,131,698

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	17. RELATED PARTY TRANSACTIONS Timothy Tyson On May 19, 2016, the Company issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Tyson as compensation for services rendered. These options vest equally over a period of 36 months. On July 6, 2016, the Company entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $100,000 to Mr. Tyson in consideration of $100,000. The Bridge Note matures on June 30, 2017. The Bridge Note, together with interest thereon was repaid on August 8, 2016. In connection with the Bridge Note above, on July 6, 2016, Mr. Tyson was issued five year warrants to acquire 15,000 shares of common stock exercisable at $3.50 per share. Michael Taglich On May 19, 2016, the Company issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Taglich as compensation for services rendered. These options vest equally over a period of 36 months. On June 30, 2016, the Company entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $250,000 to Mr. Taglich in consideration of $250,000. The Bridge Note matures on June 30, 2017. The Bridge Note, together with interest thereon was repaid on August 8, 2016. In connection with the Bridge Note above, on June 30, 2016, Mr. Taglich was issued five year warrants to acquire 37,500 shares of common stock exercisable at $3.50 per share. Vincent Palmieri On May 19, 2016, the Company issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Palmieri as compensation for services rendered. These options vest equally over a period of 36 months. On June 30, 2016, the Company entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $50,000 to Mr. Palmieri in consideration of $50,000. The Bridge Note matures on June 30, 2017. The Bridge Note, together with interest thereon was repaid on August 8, 2016. In connection with the Bridge Note above, on June 30, 2016, Mr. Palmieri was issued five year warrants to acquire 7,500 shares of common stock exercisable at $3.50 per share. Clive Kabatznik On May 19, 2016, the Company issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Kabatznik as compensation for services rendered. These options vest equally over a period of 36 months. On June 30, 2016, the Company entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $50,000 to Mr. Kabatznik in consideration of $50,000 in cash. The Bridge Note matures on June 30, 2017. The Bridge Note, together with interest thereon was repaid on August 8, 2016. In connection with the Bridge Note above, on June 30, 2016, Mr. Kabatznik was issued five year warrants to acquire 7,500 shares of common stock exercisable at $3.50 per share. Edward Roffman On June 16, 2015, pursuant to the terms of a restricted stock award, 19,000 restricted shares were issued to the Chairman of our audit committee who is also a board director, as a once off compensation expense for his services as chairman of the audit committee. As of June 30, 2016, all of these shares are vested. On May 19, 2016, the Company issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Roffman as compensation for services rendered. These options vest equally over a period of 36 months. On June 30, 2016, the Company entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $25,000 to Mr. Roffman in consideration of $25,000. The Bridge Note matures on June 30, 2017. The Bridge Note, together with interest thereon was repaid on August 8, 2016. In connection with the Bridge Note above, on June 30, 2016, Mr. Roffman was issued five year warrants to acquire 3,750 shares of common stock exercisable at $3.50 per share. Douglas Krafte On February 25, 2016, upon the resignation of Dr. Benjamin Warner, as our Chief Scientific Officer, Douglas Krafte, age 56, the Chief Scientific Officer of our subsidiary Icagen Corp., was appointed to the position of Chief Scientific Officer for Icagen Inc. and its subsidiaries. The Company has not entered into an employment agreement with Dr. Krafte; however, in accordance with the terms of its acquisition of the assets of the subsidiary of Pfizer, Inc., the Company has agreed to continue to pay Dr. Krafte his current annual salary of $251,600, together with health insurance payments, 401K contributions and an annual incentive plan targets of 25% of his base salary until June 30, 2017 as well as severance payments in the event of his termination of employment. On May 19, 2016, the Company issued ten-year options exercisable for 100,000 shares of common stock at $3.50 per common shares to Mr. Krafte as compensation for services rendered. These options vested as to 25,000 options on June 30, 2016 and the remaining 75,000 equally over a period of 36 months, commencing on July 1, 2016. Benjamin Warner As of June 30, 2016 and December 31, 2015, Dr. Benjamin Warner owned 23.1% of the issued and outstanding shares of common stock on an un-diluted basis. Richard Cunningham Pursuant to the terms of an employment agreement entered into with Richard Cunningham, our Chief Executive Officer, stock options to purchase 250,000 shares of Common Stock were awarded to Mr. Cunningham on January 7, 2015, which options vest as follows: (i) Fifty Thousand (50,000) shares vested on November 24, 2015; (ii) One Hundred and Fifty Thousand (150,000) shares vest monthly on a pro rata basis commencing on December 31, 2015 for a period of thirty six months; and (iii) Fifty Thousand (50,000) shares vest on the November 24, 2018. The exercise price for the options is $3.50 per share. Upon a change of control, as defined in the Company’s existing stock option plan, all unvested options issued to Mr. Cunningham shall become fully vested immediately upon the change of control. First South Africa Management The Company incurred an expense of $90,000 for services provided by First South Africa Management for provision of CFO services by Mr. Korb and $21,000 for bookkeeping services for the six months ended June 30, 2016.

Operating Leases

Operating Leases	6 Months Ended
	Jun. 30, 2016
Operating Leases [Abstract]
OPERATING LEASES	18. OPERATING LEASES The Company paid for an apartment leased by one of our officers in Cambridge, Massachusetts. The lease expired on June 30, 2016 and was not renewed. Rental expense for the six months ended June 30, 2016 amounted to $15,000. The Company entered into an asset purchase agreement with Icagen, Inc., a subsidiary of Pfizer, Inc., whereby certain assets were acquired from Icagen, Inc., the agreement included the sub-letting of premises located at Research Triangle Park, Durham, North Carolina. The lease terminates on April 30, 2019. The rental expense for the six months ended June 30, 2016 amounted to $85,189. Future annual minimum payments required under operating lease obligations as of June 30, 2016, are as follows: Amount 2016 $ 85,905 2017 177,823 2018 184,047 2019 63,496 Total $ 511,271

Litigation

Litigation	6 Months Ended
	Jun. 30, 2016
Litigation [Abstract]
LITIGATION	19. LITIGATION Set forth below is a factual description of the status of Company's legal proceedings. It should not be misconstrued as the Company's acquiescence in any claimant's position with respect to such litigation. The Company continues to believe that the claims made against it do not have any merit whatsoever and intends to vigorously defend itself. There have been no material litigation developments since the filing of our Annual Report on form 10-K for the year ended December 31, 2015 and our quarterly report on form 10-Q for the three months ended March 31, 2016, other than as follows: Dentons’ dispute Litigation with estate of Sigmund Eisenschenk On May 31, 2016, Crane filed his answer and affirmative defenses to Counts I and II of the Second Amended Petition for Citation to Recover. On May 31, 2016, the Company filed a motion to dismiss Counts II, IV and V of the Second Amended Petition for Citation to Recover. On May 31, 2016, the Company also filed its answer, affirmative defenses and counterclaims to Count V and VI of the Second Amended Petition for Citation to Recover. On June 7, 2016, QTM filed an amended Count IV to the Second Amended Petition for Citation to Recover. On June 8, 2016, American Milling filed its answer to the Company’s affirmative defenses and counterclaims. On June 9, 2016, the Court denied Crane and the Company’s motions to dismiss Counts II, V and VI of the Second Amended Petition for Citation to Recover 1 On June 23, 2016, the Company filed a motion to dismiss Count IV to the Second Amended Petition for Citation to Recover. On June 23, 2016, QTM filed its reply to Aaron Crane’s affirmative defenses. On June 29, 2016, American Milling and Peter Schmiedel filed their response brief in the Appellate Court of Illinois in opposition to the Company’s appeal brief filed February 8, 2016. 1 On July 8, 2016, American Milling and Peter Schmiedel filed a motion for partial summary judgment as to Count VI (breach of contract) of the Second Amended Petition for Citation to Recover. In their motion for partial summary judgment, American Milling contend that Sigmund Eisenschenk performed his obligations under the terms of a 2005 financing agreement and is therefore entitled to a judgment against the Company for $3.2 million dollars. On July 14, 2016, the Court denied the Company’s motion for the issuance of letters rogatory. On July 15, 2016, the Company filed a motion to stay the Estate and American Millings motion for partial summary judgment as to Count VI of the Second Amended Petition for Citation to Recover. The Company also filed a motion to extend the due date for its response to the motion for partial summary judgment pending, amongst other reasons, a ruling on the motion to stay. On July 15, 2016, the Company filed a motion for leave to file a reply brief in further support of its motion to dismiss Count IV of the Second Amended Petition for Citation to Recover. On July 15, 2016, the Company filed its reply brief in the Illinois Appellate Court. The appeal in the Illinois Appellate Court is fully briefed and the parties are now awaiting a decision. On July 21, 2016, QTM filed a response in opposition to the Company’s motion to dismiss Count IV of the Second Amended Petition for Citation to Recover. No hearing date is yet scheduled. The Company’s response to the motion for partial summary judgment on Count VI of the Second Amended Petition for Citation to Recover is due August 14, 2016. The Company’s reply brief is due in the Appellate Court of Illinois by August 15, 2016. New Mexico Litigation Against the Estate of Eisenschenk The Estate of Eisenschenk filed their answer brief on June 2, 2016. The Company filed its reply brief on July 6, 2016. The parties are awaiting a decision by the New Mexico Court of Appeals.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Legal Settlement Liabilities\Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	20. COMMITMENTS AND CONTINGENCIES In terms of the asset purchase agreement entered into on July 1, 2015, with Icagen, Inc., a wholly owned subsidiary of Pfizer, Inc. the Company is required to make an additional purchase price payment of $500,000 on July 1, 2017, assuming that Pfizer satisfies its requirements under the agreement. The Company is also obligated to make earn out payments of 10% of total Gross revenues, up to a maximum of $10,000,000, commencing on revenues generated from January 1, 2017, with a minimum quarterly payment of $250,000, which payments are to be made 60 days after each quarter end.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	21. SUBSEQUENT EVENTS On July 15, 2016, Icagen-T, Inc. (“Icagen-T”), a wholly owned subsidiary of Icagen, Inc. (“Icagen”) consummated the transactions with Sanofi US Services Inc. (“Sanofi”) contemplated by the Asset Purchase Agreement dated June 27, 2016 (the “Sanofi Asset Purchase Agreement”), pursuant to which Icagen-T acquired certain assets of Sanofi that include the (i) Tucson Research Center, a two story laboratory and office building with approximately 113,950 square feet of space located in the Town of Oro Valley, Pima County, Arizona (the “Facility”), and the land on which the Facility is built; and (ii) certain machinery and equipment located at the Facility. The cash purchase price under the Sanofi Asset Purchase Agreement was $1.00. Icagen-T assumed certain liabilities, offered to continue the employment of up to 46 employees at the Facility for at least two years and maintain the Sanofi chemical libraries that will remain at the Facility. Upon the closing of the Sanofi Asset Purchase Agreement, on July 15, 2016, Icagen-T and Sanofi entered into a Master Services Agreement (the “MSA”). The MSA contains terms requiring that Icagen-T perform certain contract research for Sanofi, including, but not limited to, compound testing services. Pursuant to the terms of the MSA, Sanofi will make payments (the “Subsidy Payments”) to Icagen-T in consideration of Icagen-T’s provision of services (including maintenance of the chemical libraries) in the aggregate amount of $32 million over the next five years of which: (i) $16.5 million is expected to be paid in year 1 with $11.9 million paid at closing; (ii) $9.5 million is expected to be paid in year 2; (iii) $3 million is expected to be paid in year 3; (iv) $2 million is expected to be paid in year 4; and (v) $1 million is expected to be paid in year 5. The Subsidy Payments are to be credited against all direct service costs for which Icagen-T performs services, and in the event the Subsidy Payments exceed the direct service costs, a maximum aggregate credit of $2 million will be carried forward to subsequent years during the term of the MSA. The term of the MSA is five years with the right for both parties to mutually agree to extend the term for an additional five years and the right for Sanofi, at its sole option, to extend the term with regard to the maintenance of the Chemical Library (as defined in the Sanofi Asset Purchase Agreement) for an additional five years. Upon the closing of the Sanofi Asset Purchase Agreement, on July 15, 2016, Icagen-T executed a Deed of Trust providing Sanofi with a five year, $5 million lien on the Facility, securing performance of Icagen-T’s obligations under the MSA and the Sanofi Asset Purchase Agreement. The lien is subject to termination upon the payment by Icagen-T of $5 million to Sanofi. The parties have also agreed to a Special Warranty Deed with a Right of Reverter (“Deed of Sale”) that will revest in Sanofi all rights in the Facility in the event that Icagen-T sells the Facility at any time within the next five years and upon certain other events related to the leasing of space at the Facility. The reversion rights of Sanofi under the Deed of Sale will terminate after five years as well as upon payment of the $5 million to extinguish the lien created by the Deed of Trust. In addition, in order to facilitate the provision of the services under the MSA, Sanofi agreed to provide transitional services pursuant to the terms of a transition services agreement that was entered into at closing of the Sanofi Asset Purchase Agreement and Icagen-T was granted the right and license to use two chemical libraries located at the Facility pursuant to two separate hit discovery services agreements between the parties. As previously reported, on July 1, 2015, Icagen consummated the acquisition of certain assets of a wholly owned subsidiary of Pfizer Inc. pursuant to a Purchase and Collaboration Agreement (the “Pfizer APA”) entered into on June 26, 2015 by and between Icagen (f/k/a XRpro Sciences, Inc.) and Pfizer Research (NC), Inc. (f/k/a Icagen, Inc., “Pfizer”). As a condition to closing the Sanofi Asset Purchase Agreement, Icagen entered into an amendment to the Pfizer APA (the “Amended Pfizer APA”), which, among other things, amended the terms of the quarterly earn out payments to provide that Icagen will pay to Pfizer quarterly earn out payments commencing May 2017 equal to the greater of: (i) 10% of Aggregate Revenue (as defined in the Amended Pfizer APA) for the relevant quarter; or (ii) $250,000, up to an aggregate maximum of $10 million in Earn Out Payments (the “Maximum Earn Out Payment”). The Amended Pfizer APA also states that Aggregate Revenue for purposes of the Pfizer APA excludes: (a) amounts paid by Sanofi or its affiliates to Icagen-T under the MSA, and other ancillary agreements entered into with Sanofi or any other agreement in connection with the operation by Icagen-T of the assets acquired under the Sanofi Asset Purchase Agreement; (b) amounts paid to Icagen-T from third parties during the five year period commencing on the Effective Time (as defined in the Amended Pfizer APA) in connection with the operation by Icagen-T of the assets acquired under the Sanofi Asset Purchase Agreement; and (c) amounts paid to Icagen-T by Sanofi, its affiliates or third parties for the provision of services by Icagen-T requiring the use of Sanofi’s Library of Compounds (as defined in the MSA) located at 2090 E. Innovation Park Drive, Oro Valley, AZ 85755. Pursuant to the terms of the Amended Pfizer APA, Icagen also agreed that Icagen will not and it will cause Icagen-T not to, (A) run assays or perform other contract research services, in each case, that Icagen could reasonably provide by utilizing assets it acquired pursuant to the Pfizer APA, other than services performed or to be performed by Icagen-T for Sanofi or its affiliates under the MSA; or (B) perform or engage in ion channel screening. Other than disclosed above, the Company has evaluated subsequent events through the date the unaudited condensed consolidated financial statements were available to be issued, and has concluded that no such events or transactions took place that would require disclosure herein.

Accounting Policies and Estim27

Accounting Policies and Estimates (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies and Estimates [Abstract]
General	General The following (a) consolidated balance sheets as of June 30, 2016 which have been derived from the unaudited condensed consolidated financial statements and December 31, 2015, which have been derived from audited consolidated financial statements, and (b) the unaudited interim statements of operations and cash flows of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months and six months ended June 30, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2016. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission (“SEC”) on April 14, 2016.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments necessary to fairly present the results for the interim periods presented have been made. All adjustments made are of a normal and recurring nature and no non-recurring adjustments have been made in the presentation of these interim financial statements. All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Consolidation	Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has a majority voting interest. Investments in affiliates are accounted for under the cost method of accounting, where appropriate. All significant inter-company accounts and transactions have been eliminated in the condensed consolidated financial statements. The entities included in these condensed consolidated financial statements are as follows: Icagen, Inc. - Parent Company Icagen Corp (formerly known as XRpro Corp.) - Wholly owned subsidiary Icagen-T Inc. – Wholly owned subsidiary (formed on June 16, 2016) Caldera Discovery, Inc. - Wholly owned subsidiary (formed on March 27, 2015) XRpro Sciences, Inc. – Wholly owned subsidiary (formed on December 10, 2015)
Estimates	Estimates The preparation of these consolidated financial statements in accordance with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts and recovery of long-lived assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, the valuation of certain assets and intangibles acquired from Icagen, and assumptions used in assessing impairment of long-term assets and the assumptions used in determining percentage of completion on our long-term contracts.
Concentrations of credit risk	Concentrations of credit risk The Company maintains cash with major financial institutions. The Federal Deposit Insurance Corporation (“FDIC”) provides insurance coverage for deposits of corporations, the current limit of coverage is $250,000. As a result of this coverage the Company has cash balances of $555,190 that are not covered by the FDIC as of June 30, 2016.
Concentration of major customers	Concentration of major customers The Company derives its revenues from commercial pharmaceutical and biotechnology companies as well as from Government research contracts and Government grants. Total revenues by customer type are as follows: Three months ended June 30, 2016 Three months ended June 30, 2015 Six months ended June 30, 2016 Six months ended June 30, 2015 National Institutes of Health $ 151,403 $ 95,158 $ 266,269 $ 125,811 Commercial revenues 1,006,055 - 1,792,055 - $ 1,157,458 $ 95,158 $ 2,058,324 $ 125,811
Accounts receivable and other receivables	Accounts receivable and other receivables We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. As a basis for accurately estimating the likelihood of collection of our accounts receivable, we consider a number of factors when determining reserves for uncollectable accounts. We believe that we use a reasonably reliable methodology to estimate the collectability of our accounts receivable. We review our allowances for doubtful accounts on a regular basis. We also consider whether the historical economic conditions are comparable to current economic conditions. If the financial condition of our customers or other parties that we have business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The balance of the receivables provision as at June 30, 2016 and December 31, 2015 was $Nil and $19,084, respectively. The amount charged to bad debt provision for the three months and six months ended June 30, 2016 was $19,084 and for the three months and six months ended June 30, 2015 was $0.
Revenue recognition	Revenue recognition Revenue sources consist of commercial contracts, government grants and government contracts. We enter into fixed fee commercial development contracts that are not associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under such contracts is generally recognized upon delivery or as the development is performed. We account for our long-term Firm Fixed Price Government contracts and grants associated with the delivery of research on drug candidates and the development of drug candidates using the percentage-of-completion accounting method. Under this method, revenue is recognized based on the extent of progress towards completion of the long-term contract. We generally use the cost-to-cost measure of progress for all of our long-term contracts, unless we believe another measure will produce a more reliable result. We believe that the cost-to-cost measure is the best and most reliable performance indicator of progress on our long-term contracts as all our contract estimates are based on costs that we expect to incur in performing our long-term contracts and we have not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the long-term contract. Revenues, including estimated fees or profits are recorded as costs are incurred. When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined.
Research and Development	Research and Development The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred. Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life. The amount expensed for unrecovered research costs, included in Selling, general and administrative expenses during the three months and six months ended June 30, 2016 was $Nil and for the three months and six months ended June 30, 2015 was $75,034 and $102,900, respectively.
Related parties	Related parties Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged. Property purchased from a related party is recorded at the cost to the related party and any payment to or on behalf of the related party in excess of the cost is reflected as a distribution to the related party.
Recent accounting pronouncements	Recent accounting pronouncements In April 2016, the Financial Accounting Standards Board (FASB) issued an Accounting Standards Update (ASU) “ASU 2016 – 10 Revenue from Contract with Customers: identifying Performance Obligations and Licensing”. The amendments in this Update clarify the two following aspects (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments in this Update are intended to reduce the degree of judgement necessary to comply with Topic 606. This guidance has no effective date as yet. The Company is currently evaluating the impact of adopting this guidance. Any new accounting standards, not disclosed above, that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

Accounting Policies and Estim28

Accounting Policies and Estimates (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Policies and Estimates [Abstract]
Summary of total revenues by major customer type	Three months ended June 30, 2016 Three months ended June 30, 2015 Six months ended June 30, 2016 Six months ended June 30, 2015 National Institutes of Health $ 151,403 $ 95,158 $ 266,269 $ 125,811 Commercial revenues 1,006,055 - 1,792,055 - $ 1,157,458 $ 95,158 $ 2,058,324 $ 125,811

Prepaid Expenses and Other Cu29

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Prepaid Expenses and Other Current Assets [Abstract]
Summary of prepaid expenses and other current assets	June 30, December 31, Prepaid insurance $ 46,445 $ 19,714 Prepaid rent 2,500 2,500 Prepaid equipment maintenance 2,160 15,123 Prepaid Subscriptions 1,881 5,106 Surety bond 310,000 310,000 Other 790 5,111 $ 363,776 $ 357,554

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Intangible Assets [Abstract]
Summary of Intangible assets	June 30, December 31, Cost Amortization and impairment Net book value Net book value Cell lines $ 5,000,500 $ - $ 5,000,500 $ 5,000,500 Biology platform 1,450,500 (145,050 ) 1,305,450 1,377,975 Trade name and trademarks 637,500 - 637,500 637,500 Assembled workforce 282,500 (28,250 ) 254,250 268,375 Patents 972,000 (558,318 ) 413,682 439,523 $ 8,343,000 $ (713,618 ) $ 7,611,382 $ 7,723,873
Summary of amortization expense for future years	Amount 2016 $ 112,492 2017 224,984 2018 224,984 2019 224,984 2020 224,984 2021 and thereafter 960,954 Total $ 1,973,382

Plant and Equipment (Tables)

Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2016
Plant and Equipment [Abstract]
Components of plant and equipment	June 30, December 31, Cost Amortization and impairment Net book value Net book value Leasehold improvements $ 4,263 $ (964 ) $ 3,299 $ 3,960 Laboratory equipment 2,333,017 (588,497 ) 1,744,520 1,339,119 Computer Software 253,028 (133,180 ) 119,848 194,076 Computer equipment 28,572 (8,906 ) 19,666 24,427 $ 2,618,880 $ (731,547 ) $ 1,887,333 $ 1,561,582

Other Payables and Accrued Ex32

Other Payables and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2016
Other Payables and Accrued Expenses [Abstract]
Schedule of other payables and accrued expenses	June 30, December 31, Credit card liabilities $ 7,254 $ - Vacation and Sick Pay accrual 104,281 93,104 Payroll liabilities 271,062 174,399 Severance cost accrual - 67,315 Other 60,774 183,790 $ 443,371 $ 518,608

Legal Settlement Liabilities (T

Legal Settlement Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Legal Settlement Liabilities\Commitments and Contingencies [Abstract]
Schedule of legal settlement liability	June 30, December 31, Legal Settlement accrual – Bellows matter $ - $ 466,250 Legal settlement accrual – Eisenschenk matter 516,250 516,250 Legal settlement – other 10,000 10,000 Judgement liability 172,250 172,250 $ 698,500 $ 1,164,750

Loans Payable (Tables)

Loans Payable (Tables)	6 Months Ended
	Jun. 30, 2016
Loans Payable [Abstract]
Schedule of loans payable	June 30, December 31, Short term portion Los Alamos County project participation loan $ - $ 142,502 Asset leasing arrangement 540,186 - Asset funding agreement 6,673 21,879 Total $ 546,859 $ 164,381
Schedule of amortization of principal outstanding of loans payable	Amount Within 1 year $ 546,859

Bridge Notes (Tables)

Bridge Notes (Tables)	6 Months Ended
	Jun. 30, 2016
Bridge Notes [Abstract]
Schedule of bridge notes	June 30, December 31, Short term portion Bridge notes $ 1,045,000 $ - Accrued interest 1,447 - Unamortized debt discount (203,214 ) - Total $ 843,233 $ -

Deferred Purchase Considerati36

Deferred Purchase Consideration (Tables)	6 Months Ended
	Jun. 30, 2016
Deferred Purchase Consideration [Abstract]
Schedule of deferred purchase consideration	June 30, December 31, Short term portion Deferred purchase consideration $ 250,000 $ 125,000 Long term portion Deferred purchase consideration 10,250,000 10,500,000 10,500,000 10,625,000 Present value discount on future payments (2,468,700 ) (2,468,700 ) Imputed interest expense 570,280 282,190 Total $ 8,601,580 $ 8,438,490

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2016
Common Stock and Preferred Stock [Abstract]
Schedule of restricted stock outstanding and exercisable	Restricted Stock Outstanding Restricted Stock Exercisable Grant date Price Number Outstanding Weighted Average Number Vested Weighted Average $ 3.50 19,000 $ 3.50 19,000 $ 3.50

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2016
Warrants [Abstract]
Summary of fair value assumptions of warrant	Six months ended Calculated stock price $ 3.50 Risk-free interest rate 1.01 % Expected life of warrants (in years) 5 Expected volatility of the underlying stock 53 % Expected dividend rate 0 %
Schedule of warrant activity	Shares Exercise price per share Weighted average exercise price Outstanding January 1, 2016 2,146,970 $ 3.50 -11.40 $ 4.28 Granted 156,750 3.50 3.50 Forfeited/Cancelled (131,374 ) 11.40 11.40 Exercised - - - Outstanding June 30, 2016 2,172,346 $ 3.50-11.40 $ 3.79
Shedule of warrants outstanding and exercisable	Warrants Outstanding Warrants Exercisable Exercise Price Number of Weighted Weighted Number of Weighted $ 3.50 1,810,615 3.66 1,810,615 $ 3.85 143,401 4.00 143,401 $ 4.00 7,500 0.34 7,500 $ 4.20 150,000 1.66 150,000 $ 11.40 60,830 0.22 60,830 2,172,346 3.51 $ 3.79 2,172,346 $ 3.79

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Stock Based Compensation [Abstract]
Summary of weighted average assumptions using black-scholes pricing model	Six months ended Calculated stock price $ 3.50 Risk-free interest rate 1.81 % Expected life of options (in years) 10 Expected volatility of the underlying stock 61 % Expected dividend rate 0 %
Summary of changes stock option activity	Shares Exercise price per share Weighted average exercise price Outstanding January 1, 2016 908,270 $ 0.40 -11.42 $ 3.60 Granted 302,500 3.50 3.50 Forfeited/Cancelled (110,000 ) 2.20 2.20 Exercised - - - Outstanding June 30, 2016 1,100,770 $ 0.40-11.42 $ 3.71
Summary of information about stock options outstanding	Options Outstanding Options Exercisable Exercise Price Number of Weighted Weighted Number of Weighted $ 0.40 15,000 5.84 15,000 $ 3.00 312,500 6.71 312,500 $ 3.50 552,500 9.27 110,925 $ 4.00 56,770 0.84 56,770 $ 5.00 128,500 4.49 120,167 $ 11.42 35,500 2.43 35,500 1,100,770 7.28 $ 3.77 650,862 $ 3.94

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2016
Net Loss Per Common Share [Abstract]
Summary of dilutive shares exercise of outstanding stock instruments	Three and Six months ended Three and Six months ended Options to purchase shares of common stock 1,100,770 932,228 Warrants 2,172,346 2,146,970 Series A convertible, redeemable preferred stock - 52,500 3,273,116 3,131,698

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended
	Jun. 30, 2016
Operating Leases [Abstract]
Summary of future annual minimum payments required under operating lease obligations	Amount 2016 $ 85,905 2017 177,823 2018 184,047 2019 63,496 Total $ 511,271

Accounting Policies and Estim42

Accounting Policies and Estimates (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Summary of revenues by major customer type
Total revenues	$ 1,157,458	$ 95,158	$ 2,058,324	$ 125,811
National Institutes of Health [Member]
Summary of revenues by major customer type
Total revenues	151,403	95,158	266,269	125,811
Commercial Revenues [Member]
Summary of revenues by major customer type
Total revenues	$ 1,006,055		$ 1,792,055

Accounting Policies and Estim43

Accounting Policies and Estimates (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Accounting Policies and Estimates (Textual)
Cash balances insured by FDIC	$ 250,000		$ 250,000
Cash balances uninsured by FDIC	555,190		555,190
Balance of bad debt provision					$ 19,084
Amount credited to bad debt provision	19,084		(19,084)
Selling, general and administrative expenses		$ 75,034		$ 102,900

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Going Concern [Abstract]
Net loss	$ (1,181,436)	$ (1,326,163)	$ (2,290,963)	$ (2,754,081)	$ (8,676,037)
Accumulated deficit	(24,433,789)		(24,433,789)		(22,142,825)
Working capital	$ 1,481,192		$ 1,481,192		$ 736,629

Prepaid Expenses and Other Cu45

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid insurance	$ 46,445	$ 19,714
Prepaid rent	2,500	2,500
Prepaid equipment maintenance	2,160	15,123
Prepaid Subscriptions	1,881	5,106
Surety bond	310,000	310,000
Other	790	5,111
Prepaid expense and other assets current, Total	$ 363,776	$ 357,554

Prepaid Expenses and Other Cu46

Prepaid Expenses and Other Current Assets (Details Textual) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Prepaid Expenses And Other Current Assets (Textual)
Surety bond	$ 310,000	$ 310,000

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Summary of licenses cost
Cost	$ 8,343,000
Amortization and impairment	(713,618)
Net book value	7,611,382	$ 7,723,873
Cell lines [Member]
Summary of licenses cost
Cost	5,000,500
Amortization and impairment
Net book value	5,000,500	5,000,500
Biology platform [Member]
Summary of licenses cost
Cost	1,450,500
Amortization and impairment	(145,050)
Net book value	1,305,450	1,377,975
Trade name and trademarks [Member]
Summary of licenses cost
Cost	637,500
Amortization and impairment
Net book value	637,500	637,500
Assembled Workforce [Member]
Summary of licenses cost
Cost	282,500
Amortization and impairment	(28,250)
Net book value	254,250	268,375
Patents [Member]
Summary of licenses cost
Amortization and impairment	(558,318)
Net book value	$ 413,682	$ 439,523

Intangible Assets (Details 1)

Intangible Assets (Details 1)	Jun. 30, 2016USD ($)
Summary of amortization expense for future years
2,016	$ 112,492
2,017	224,984
2,018	224,984
2,019	224,984
2,020	224,984
2021 and thereafter	960,954
Total	$ 1,973,382

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Intangible Assets (Textual)
Amortization expense	$ 56,246	$ 12,921	$ 112,492	$ 25,842

Plant and Equipment (Details)

Plant and Equipment (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Components of Plant and equipment
Cost	$ 2,618,880
Amortization and impairment	(731,547)
Net book value	1,887,333	$ 1,561,582
Computer Software [Member]
Components of Plant and equipment
Cost	253,028
Amortization and impairment	(133,180)
Net book value	119,848	194,076
Leasehold improvements [Member]
Components of Plant and equipment
Cost	4,263
Amortization and impairment	(964)
Net book value	3,299	3,960
Laboratory equipment [Member]
Components of Plant and equipment
Cost	2,333,017
Amortization and impairment	(588,497)
Net book value	1,744,520	1,339,119
Computer equipment [Member]
Components of Plant and equipment
Cost	28,572
Amortization and impairment	(8,906)
Net book value	$ 19,666	$ 24,427

Plant and Equipment (Details Te

Plant and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Plant and Equipment [Abstract]
Depreciation	$ 112,304	$ 32,823	$ 213,881	$ 65,049

Other Payables and Accrued Ex52

Other Payables and Accrued Expenses (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Summary of other payables and accrued expenses
Credit card liabilities	$ 7,254
Vacation and Sick Pay accrual	104,281	93,104
Payroll liabilities	271,062	174,399
Severance cost accrual		67,315
Other	60,774	183,790
Other payables and accrued expenses	$ 443,371	$ 518,608

Legal Settlement Liabilities (D

Legal Settlement Liabilities (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Schedule of legal settlement liability
Legal settlement accrual	$ 698,500	$ 1,164,750
Legal Settlement accrual - Bellows matter [Member]
Schedule of legal settlement liability
Legal settlement accrual		466,250
Legal settlement accrual - Eisenschenk matter [Member]
Schedule of legal settlement liability
Legal settlement accrual	516,250	516,250
Legal settlement - other [Member]
Schedule of legal settlement liability
Legal settlement accrual	10,000	10,000
Judgement liability [Member]
Schedule of legal settlement liability
Legal settlement accrual	$ 172,250	$ 172,250

Legal Settlement Liabilities 54

Legal Settlement Liabilities (Details Textual) - USD ($)	Sep. 28, 2015	Jun. 30, 2016	Dec. 31, 2015
Legal Settlement Liabilities (Textual)
Legal settlement for cash	$ 1,650,000
Series A Preferred Stock
Legal Settlement Liabilities (Textual)
Convertible redeemable preferred stock, shares issued			105,000

Loans Payable (Details)

Loans Payable (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Schedule of loans payable
Total	$ 546,859	$ 164,381
Los Alamos County project participation loan [Member]
Schedule of loans payable
Total		142,502
Asset leasing arrangement [Member]
Schedule of loans payable
Total	540,186
Asset funding agreement [Member]
Schedule of loans payable
Total	$ 6,673	$ 21,879

Loans Payable (Details 1)

Loans Payable (Details 1)	Jun. 30, 2016USD ($)
Schedule of amortization of principal outstanding on loans payable
Within 1 year	$ 546,859

Loans Payable (Details Textual)

Loans Payable (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Apr. 21, 2016	Jun. 30, 2016	Dec. 31, 2015
Loans Payable (Textual)
Total		$ 546,859	$ 164,381
Los Alamos County project participation loan [Member]
Loans Payable (Textual)
Total			142,502
Asset leasing arrangement [Member]
Loans Payable (Textual)
Interest rate	6.70%
Equal monthly repayments, amount	$ 28,751
Term of loan	12 months
Debt Instrument, Description	The lease consists of twelve equal monthly instalments of $28,751 each with a remaining balance due of $225,000 at the end of the twelve-month period.
Future payments	$ 533,290
Interest expense	36,772
Remaining debt amount	$ 225,000
Asset funding arrangement [Member]
Loans Payable (Textual)
Interest rate		11.80%
Equal monthly repayments, amount		$ 2,313
Term of loan		12 months
Proceeds from software acquisition loan		$ 26,062
Debt Instrument, Description		The term of the loan is for twelve months with 12 equal installments of $2,313.
Total		$ 6,673	$ 26,062

Bridge Notes (Details)

Bridge Notes (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Short term portion
Bridge notes	$ 1,045,000
Accrued interest	1,447
Unamortized debt discount	(203,214)
Total	$ 843,233

Bridge Notes (Details Textual)

Bridge Notes (Details Textual)	Jul. 07, 2016USD ($)UnitInvestors	Jun. 30, 2016USD ($)UnitInvestors$ / sharesshares	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)$ / shares
Gross proceeds		$ 1,045,000
Common stock, par value | $ / shares		$ 0.001		$ 0.001
Unamortized debt discount		$ 203,214
Investor [Member] | Subsequent Event [Member]
Number of units sold | Unit	114.5
Gross proceeds	$ 1,145,000
Proceeds from sale of equity	$ 1,145,000
Private Placement [Member] | Investor [Member] | Subsequent Event [Member]
Number of investors | Investors	1
Number of units sold | Unit	10
Proceeds from sale of equity	$ 100,000
Placement Agent Warrants [Member]
Warrants exercisable | shares		171,750
Unamortized debt discount		$ 203,214
Interest rate		6.00%
Gross proceeds		$ 1,145,000
Public offering reimburse amount		$ 15,000
Warrant issued to placement agent | shares		28,625
Exercise price of warrant | $ / shares		$ 3.50
Sold of common stock | shares		2,500
Principal amount of notes sold		$ 100,000
Amount of additional warrant issued		$ 27,066
Placement Agent Warrants [Member] | Subsequent Event [Member]
Amount of warrant issued	$ 14,183
Securities Purchase Agreement [Member]
Number of investors | Investors		11
Number of units sold | Unit		104.5
Bridge notes,description		The Company sold in a private placement offering to 11 investors pursuant to a securities purchase agreement entered into with each investor, 104.5 units at a per unit price of $10,000, each unit (the "Units") consisting of a note in the principal amount of $10,000 (the "Notes") and a five-year warrant (the "Warrants") to acquire 1,500 shares of the Company's common stock, par value, $0.001 per share, at an exercise price of $3.50 per share for gross proceeds of $1,045,000.
Gross proceeds		$ 1,045,000
Warrants exercise price per share | $ / shares		$ 3.50
Securities Purchase Agreement [Member] | Subsequent Event [Member]
Number of units sold | Unit	10
Gross proceeds	$ 100,000
Security and Pledge Agreement [Member]
Debt instrument,interest rate per annum		8.00%
Debt instrument, maturity date		Jun. 30, 2017
Debt instrument monthly interest rate		1.00%

Deferred Purchase Considerati60

Deferred Purchase Consideration (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Short term portion
Deferred purchase consideration	$ 250,000	$ 125,000
Long term portion
Deferred purchase consideration	8,351,580	8,313,490
Total	10,500,000	10,625,000
Present value discount on future payments	(2,468,700)	(2,468,700)
Imputed interest expense	570,280	282,190
Total	$ 8,601,580	$ 8,438,490

Deferred Purchase Considerati61

Deferred Purchase Consideration (Details Textual)	6 Months Ended
	Jun. 30, 2016
Deferred Purchase Consideration (Textual)
Deferred purchase consideration, description	In terms of the Icagen asset purchase agreement entered into on July 1, 2015, the Company has the following deferred purchase price obligations: ● $500,000 is due on July 1, 2017, provided that Pfizer has generated at least $4,000,000 in revenue, there are no indications that the targets will not be met; ● commencing January 1, 2017, the Company is obligated to pay additional purchase price consideration calculated as 10% (ten percent) of gross revenues to Pfizer, Inc. This obligation is capped at a maximum of $10,000,000. These earn out payments are payable quarterly, 60 days after the completion of each calendar quarter, with a minimum payment of $250,000 per quarter. There are no indications that the Company will not meet the maximum earn out payment.

Preferred Stock (Details)

Preferred Stock (Details) - Series A Preferred Stock - shares	Jun. 30, 2016	Dec. 31, 2015
Preferred Stock (Textual)
Convertible redeemable preferred stock, shares issued		105,000
Convertible redeemable preferred stock, shares outstanding		105,000

Common Stock (Details)

Common Stock (Details) - 3.50 [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Restricted Stock Exercisable, Number Vested | shares	19,000
Restricted Stock Exercisable, Weighted Average Grant Date Price | $ / shares	$ 3.50

Common Stock (Details Textual)

Common Stock (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 16, 2015
Common Stock (Textual)
Restricted stock award shares issued to the chairman of the audit committee			19,000
Restricted stock expense	$ 19,950	$ 0

Warrants (Details)

Warrants (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2016$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Calculated stock price	$ 3.50
Risk-free interest rate	1.01%
Expected life of warrants (in years)	5 years
Expected volatility of the underlying stock	53.00%
Expected dividend rate	0.00%

Warrants (Details 1)

Warrants (Details 1) - Warrant [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Outstanding, Beginning balance | shares	2,146,970
Shares Granted | shares	156,750
Shares, Forfeited/Cancelled | shares	(131,374)
Shares Exercised | shares
Shares Outstanding, Ending balance | shares	2,172,346
Exercise price per share, Granted	$ 3.50
Exercise price per share Forfeited/Cancelled	11.40
Exercise price per share, Exercised
Weighted Average Exercise Price, Beginning Balance	4.28
Weighted average exercise price, Granted	3.50
Weighted average exercise price, Forfeited/Cancelled	11.40
Weighted average exercise price, Exercised
Weighted Average Exercise Price, Ending Balance	3.79
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share, Beginning balance	3.50
Exercise price per share, Ending balance	3.50
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share, Beginning balance	11.40
Exercise price per share, Ending balance	$ 11.40

Warrants (Details 2)

Warrants (Details 2) - Warrant [Member] - $ / shares	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Outstanding And Exercisable Warrants [Abstract]
Number of shares, warrants outstanding	2,172,346	2,146,970
Weighted average remaining contractual years, warrants outstanding	3 years 6 months 4 days
Weighted average exercise price, warrants outstanding	$ 3.79	$ 4.28
Number of shares, warrants exercisable	2,172,346
Weighted average exercise price, warrants exercisable	$ 3.79
Exercise Price 3.50 [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$ 3.50
Number of shares, warrants outstanding	1,810,615
Weighted average remaining contractual years, warrants outstanding	3 years 7 months 28 days
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	1,810,615
Weighted average exercise price, warrants exercisable
Exercise Price 3.85 [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$ 3.85
Number of shares, warrants outstanding	143,401
Weighted average remaining contractual years, warrants outstanding	4 years
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	143,401
Weighted average exercise price, warrants exercisable
Exercise Price 4.00 [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$ 4
Number of shares, warrants outstanding	7,500
Weighted average remaining contractual years, warrants outstanding	4 months 2 days
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	7,500
Weighted average exercise price, warrants exercisable
Exercise Price 4.20 [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$ 4.20
Number of shares, warrants outstanding	150,000
Weighted average remaining contractual years, warrants outstanding	1 year 7 months 28 days
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	150,000
Weighted average exercise price, warrants exercisable
Exercise Price 11.40 [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$ 11.40
Number of shares, warrants outstanding	60,830
Weighted average remaining contractual years, warrants outstanding	2 months 19 days
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	60,830
Weighted average exercise price, warrants exercisable

Warrants (Details Textual)

Warrants (Details Textual)	Jul. 07, 2016USD ($)UnitInvestors	Jun. 30, 2016USD ($)UnitInvestors$ / sharesshares	Dec. 31, 2015USD ($)$ / shares
Warrants (Textual)
Unamortized debt discount		$ 203,214
Common stock, par value | $ / shares		$ 0.001	$ 0.001
Warrant [Member]
Warrants (Textual)
Warrants expired | shares		131,374
Exercise Price | $ / shares		$ 11.40
Investor [Member] | Subsequent Event [Member]
Warrants (Textual)
Number of units sold | Unit	114.5
Proceeds from sale of equity	$ 1,145,000
Private Placement [Member] | Investor [Member] | Subsequent Event [Member]
Warrants (Textual)
Number of investors | Investors	1
Number of units sold | Unit	10
Proceeds from sale of equity	$ 100,000
Placement Agent Warrants [Member]
Warrants (Textual)
Warrants exercisable to purchase common stock,shares | shares		171,750
Unamortized debt discount		$ 203,214
Commission from offering		6.00%
Placement Agent Warrants [Member] | Subsequent Event [Member]
Warrants (Textual)
Additional units issued value	14,183
Additional allocated value	$ 27,066
Securities Purchase Agreement [Member]
Warrants (Textual)
Number of investors | Investors		11
Number of units sold | Unit		104.5
Share Price | $ / shares		$ 10,000
Warrants exercise price per share | $ / shares		$ 3.50
Debt Instrument, Description		Each unit (the "Units") consisting of a note in the principal amount of $10,000 (the "Notes") and a five-year warrant (the "Warrants") to acquire 1,500 shares of the Company's common stock, par value, $0.001 per share

Stock Based Compensation (Detai

Stock Based Compensation (Details) - Stock Options [Member]	6 Months Ended
	Jun. 30, 2016$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Calculated stock price	$ 3.50
Risk-free interest rate	1.81%
Expected life of options (in years)	10 years
Expected volatility of the underlying stock	61.00%
Expected dividend rate	0.00%

Stock Based Compensation (Det70

Stock Based Compensation (Details 1) - Stock Options [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Summary of changes in options outstanding
Shares Outstanding, Beginning balance | shares	908,270
Shares, Granted | shares	302,500
Shares, Forfeited/Cancelled | shares	(110,000)
Shares, Exercised | shares
Shares Outstanding, Ending balance | shares	1,100,770
Exercise price per share, Granted	$ 3.50
Exercise price per share Forfeited/Cancelled	2.20
Exercise price per share, Exercised
Weighted Average Exercise Price, Beginning Balance	3.60
Weighted Average Exercise Price, Granted	3.50
Weighted Average Exercise Price, Forfeited/Cancelled	2.20
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Ending Balance	3.71
Minimum [Member]
Summary of changes in options outstanding
Exercise price per share, Beginning balance	0.40
Exercise price per share, Ending balance	0.40
Maximum [Member]
Summary of changes in options outstanding
Exercise price per share, Beginning balance	11.42
Exercise price per share, Ending balance	$ 11.42

Stock Based Compensation (Det71

Stock Based Compensation (Details 2) - Stock Options [Member] - $ / shares	3 Months Ended
	Jun. 30, 2016	May 19, 2016	Dec. 31, 2015
Summary of information about stock options outstanding
Number of shares, Options Outstanding	1,100,770		908,270
Weighted average remaining contractual years, Option outstanding	7 years 3 months 11 days
Weighted Average Exercise Price, Option Outstanding	$ 3.71		$ 3.60
Number of Shares, Option exercisable	650,862	240,000
Weighted average exercise price, options exercisable	$ 3.94	$ 3.50
Exercise Price 0.40 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$ 0.40
Number of shares, Options Outstanding	15,000
Weighted average remaining contractual years, Option outstanding	5 years 10 months 2 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	15,000
Weighted average exercise price, options exercisable
Exercise Price 3.00 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$ 3
Number of shares, Options Outstanding	312,500
Weighted average remaining contractual years, Option outstanding	6 years 8 months 16 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	312,500
Weighted average exercise price, options exercisable
Exercise Price 3.50 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$ 3.50
Number of shares, Options Outstanding	552,500
Weighted average remaining contractual years, Option outstanding	9 years 3 months 7 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	110,925
Weighted average exercise price, options exercisable
Exercise Price 4.00 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$ 4
Number of shares, Options Outstanding	56,770
Weighted average remaining contractual years, Option outstanding	10 months 2 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	56,770
Weighted average exercise price, options exercisable
Exercise Price 5.00 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$ 5
Number of shares, Options Outstanding	128,500
Weighted average remaining contractual years, Option outstanding	4 years 5 months 27 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	120,167
Weighted average exercise price, options exercisable
Exercise Price 11.42 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$ 11.42
Number of shares, Options Outstanding	35,500
Weighted average remaining contractual years, Option outstanding	2 years 5 months 5 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	35,500
Weighted average exercise price, options exercisable

Stock Based Compensation (Det72

Stock Based Compensation (Details Textual) - USD ($)	May 19, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Stock Based Compensation (Textual)
Number of options related to performance				131,374
Weighted-average grant-date fair values of options granted per share				$ 2.43		$ 3.31
Fair values of options granted during period				$ 736,066		$ 844,577
Unvested options to purchase common stock		449,908		449,908
Expected unrecognized compensation cost		$ 1,193,044		$ 1,193,044
Compensation cost not yet recognized, Period for recognition				47 months
Stock based compensation charge		133,549	$ 76,913	$ 228,849	$ 293,425
Stock options outstanding, intrinsic value		$ 202,750		$ 202,750
Employee Stock Option [Member]
Stock Based Compensation (Textual)
Number of Shares, Option exercisable	240,000	650,862		650,862
Weighted average exercise price, options exercisable	$ 3.50	$ 3.94		$ 3.94
Number of options vested	220,000
Award vesting period	48 months
Number of options related to performance	20,000
Employee Stock Option [Member] | Director [Member]
Stock Based Compensation (Textual)
Number of Shares, Option exercisable	62,500
Weighted average exercise price, options exercisable	$ 3.50
Award vesting period	36 months
2015 Stock Incentive Plan [Member]
Stock Based Compensation (Textual)
Number of Shares, Option exercisable		110,000		110,000		72,282

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Summary of dilutive shares exercise of outstanding stock instruments
Anti Dilutive shares pursuant to the exercise of outstanding stock instruments	3,273,116	3,131,698	3,273,116	3,131,698
Options to purchase shares of common stock [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti Dilutive shares pursuant to the exercise of outstanding stock instruments	1,100,770	932,228	1,100,770	932,228
Warrants [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti Dilutive shares pursuant to the exercise of outstanding stock instruments	2,172,346	2,146,970	2,172,346	2,146,970
Series A convertible, redeemable preferred stock [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti Dilutive shares pursuant to the exercise of outstanding stock instruments		52,500		52,500

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Jul. 06, 2016	May 19, 2016	Feb. 25, 2016	Jun. 16, 2015	Jan. 07, 2015	Jun. 30, 2016	Dec. 31, 2015
Related Party Transactions (Textual)
Majority of common shares owned by Dr. Benjamin Warner						23.10%	23.10%
First South Africa Management [Member]
Related Party Transactions (Textual)
Expenses incurred						$ 90,000
Incurred for booking keeping services						$ 21,000
Mr. Tyson [Member]
Related Party Transactions (Textual)
Number of option exercisable		12,500
Weighted average exercise price, options exercisable		$ 3.50
Award vesting period		36 months
Term of options		10 years
Mr. Tyson [Member] | Subsequent Event [Member]
Related Party Transactions (Textual)
Bridge note percentage rate	8.00%
Bridge note amount	$ 100,000
Bridge note in exchange for cash	$ 100,000
Bridge note matures date	Jun. 30, 2017
Term of warrants	5 years
Common stock acquired	15,000
common stock exercisable price per share	$ 3.50
Mr. Taglich [Member]
Related Party Transactions (Textual)
Number of option exercisable		12,500
Weighted average exercise price, options exercisable		$ 3.50
Award vesting period		36 months
Term of options		10 years
Bridge note percentage rate						8.00%
Bridge note amount						$ 250,000
Bridge note in exchange for cash						$ 250,000
Bridge note matures date						Jun. 30, 2017
Term of warrants						5 years
Common stock acquired						37,500
common stock exercisable price per share						$ 3.50
Mr. Palmieri [Member]
Related Party Transactions (Textual)
Number of option exercisable		12,500
Weighted average exercise price, options exercisable		$ 3.50
Award vesting period		36 months
Term of options		10 years
Bridge note percentage rate						8.00%
Bridge note amount						$ 50,000
Bridge note in exchange for cash						$ 50,000
Bridge note matures date						Jun. 30, 2017
Term of warrants						5 years
Common stock acquired						7,500
common stock exercisable price per share						$ 3.50
Mr. Kabatznik [Member]
Related Party Transactions (Textual)
Number of option exercisable		12,500
Weighted average exercise price, options exercisable		$ 3.50
Award vesting period		36 months
Term of options		10 years
Bridge note percentage rate						8.00%
Bridge note amount						$ 50,000
Bridge note in exchange for cash						$ 50,000
Bridge note matures date						Jun. 30, 2017
Term of warrants						5 years
Common stock acquired						7,500
common stock exercisable price per share						$ 3.50
Edward Roffman [Member]
Related Party Transactions (Textual)
Restricted stock award				19,000
Number of option exercisable		12,500
Weighted average exercise price, options exercisable		$ 3.50
Award vesting period		36 months
Term of options		10 years
Bridge note percentage rate						8.00%
Bridge note amount						$ 25,000
Bridge note in exchange for cash						$ 25,000
Bridge note matures date						Jun. 30, 2017
Term of warrants						5 years
Common stock acquired						3,750
common stock exercisable price per share						$ 3.50
Douglas Krafte [Member]
Related Party Transactions (Textual)
Annual salary			$ 251,600
Annual incentive plan, description			An annual incentive plan targets of 25% of his base salary until June 30, 2017 as well as severance payments in the event of his termination of employment.
Number of option exercisable		100,000
Weighted average exercise price, options exercisable		$ 3.50
Award vesting period						36 months
Term of options		10 years
Options vested						25,000
Options vested remaining equally over period of shares						75,000
Mr. Richard Cunningham [Member]
Related Party Transactions (Textual)
Options granted					250,000
Exercise price					$ 3.50
Share based payment award description					(i) Fifty Thousand (50,000) shares vested on November 24, 2015; (ii) One Hundred and Fifty Thousand (150,000) shares vest monthly on a pro rata basis commencing on December 31, 2015 for a period of thirty six months; and (iii) Fifty Thousand (50,000) shares vest on the November 24, 2018.

Operating Leases (Details)

Operating Leases (Details)	Jun. 30, 2016USD ($)
Summary of future annual minimum payments required under operating lease obligations
2,016	$ 85,905
2,017	177,823
2,018	184,047
2,019	63,496
Total	$ 511,271

Operating Leases (Details Textu

Operating Leases (Details Textual)	6 Months Ended
	Jun. 30, 2016USD ($)
Purchase Agreement [Member]
Operating Leases (Textual)
Lease expiration date	Apr. 30, 2019
Rental expense	$ 85,189
Apartment Lease [Member]
Operating Leases (Textual)
Lease expiration date	Jun. 30, 2016
Rental expense	$ 15,000

Litigation (Details)

Litigation (Details) - USD ($)	Jul. 08, 2016	May 07, 2014	Apr. 22, 2016
Dentons US LLP [Member]
Litigation (Textual)
Judgment against company amount		$ 3,050,000	$ 3,050,000
Sigmund Eisenschenk [Member] | Subsequent Event [Member]
Litigation (Textual)
Judgment against company amount	$ 3,200,000

Commitments and Contingencies (

Commitments and Contingencies (Details)	6 Months Ended
	Jun. 30, 2016USD ($)
Commitments and Contingencies (Textual)
Purchase price payments	$ 500,000
Commitments description	Obligated to make earn out payments of 10% of total Gross revenues, up to a maximum of $10,000,000, commencing on revenues generated from January 1, 2017, with a minimum quarterly payment of $250,000, which payments are to be made 60 days after each quarter end.

Subsequent Events (Details)

Subsequent Events (Details) - Sanofi Asset Purchase Agreement [Member] - Subsequent Event [Member]	Jul. 15, 2016USD ($)ft²
Subsequent Events (Textual)
Square feet of space | ft²	113,950
Cash purchase price	$ 1
Services payment to be received	$ 32,000,000
Terms of payments	(i) $16.5 million is expected to be paid in year 1 with $11.9 million paid at closing; (ii) $9.5 million is expected to be paid in year 2; (iii) $3 million is expected to be paid in year 3; (iv) $2 million is expected to be paid in year 4; and (v) $1 million is expected to be paid in year 5.
Service costs maximum aggregate credit	$ 2,000,000
Asset purchase agreement Description	(i) 10% of Aggregate Revenue (as defined in the Amended Pfizer APA) for the relevant quarter; or (ii) $250,000, up to an aggregate maximum of $10 million in Earn Out Payments (the "Maximum Earn Out Payment").
Asset purchase agreement closing description	Upon the closing of the Sanofi Asset Purchase Agreement, on July 15, 2016, Icagen-T executed a Deed of Trust providing Sanofi with a five year, $5 million lien on the Facility, securing performance of Icagen-T's obligations under the MSA and the Sanofi Asset Purchase Agreement. The lien is subject to termination upon the payment by Icagen-T of $5 million to Sanofi.